Potent Small Molecule Inhibitors for HIV-1 Protease
- 總結
- The researchers have also developed a new generation of protease inhibitors that are exceedingly potent and maintain potency against multidrug resistant HIV-1 variants. Dr. Ghosh's laboratory has designed, synthesized, and evaluated several different series of compounds. These novel protease inhibitors show potent enzyme inhibitory, antiviral activity, and exceptional broad spectrum activity against highly cross-resistant mutant.
- 技術優勢
- Decreased adverse side effectsEffective against multidrug resistant HIV-1 variants Improved bioavailabilitySuperior pharmacokinetic properties
- 技術應用
- Medical/HealthcarePharmaceuticalsHIV/AIDS TreatmentDrug Development
- 詳細技術說明
- Arun GhoshGhosh GroupPurdue Chemistry
- *Abstract
-
- *Background
- Advances in the treatment of HIV/AIDS with HIV-1 protease inhibitors in combination with reverse transcriptase inhibitors, known as highly active antiretroviral therapy (HAART), has resulted in improved life expectancy and significantly reduced HIV/AIDS-related mortality in the developed world. Unfortunately, HAART suffers from adverse drug side effects, poor oral bioavailability, and drug interactions. Also, drug-resistant HIV-1 variants have begun to emerge. Development of antiretroviral therapy with broad-spectrum activity and minimal side effects is needed for current and future HIV/AIDS treatment. Purdue University researchers have developed Darunavir, brand name Prezista, a drug used to treat HIV infection. Prezista was developed by the pharmaceutical company Tibotec and is an OARAC recommended treatment option for treatment-naive and -experienced adults and adolescents. It is also used in patients with drug-resistant HIV.
- *IP Issue Date
- None
- *IP Type
- Divisional
- *Stage of Development
- Concept Developed
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry
- 國家
- United States
- 申請號碼
- None
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
